Subscribe Us

header ads

Recents

header ads

Contraceptive Drugs Market Size, Growth, Demands Outlook and Forecasts to 2030

Precedence Research - February 03, 2023

According to the research report, the global contraceptive drugs market size is expected to touch USD 25.6 Billion by 2030, from USD 16.25 Billion in 2022, growing with a significant CAGR of 5.85% from 2022 to 2030. 

Contraceptive Drugs Market Size 2021 to 2030

The contraceptive drugs report offers a comprehensive study of the current state expected at the major drivers, market strategies, and key vendors’ growth. The report presents energetic visions to conclude and study the market size, market hopes, and competitive surroundings. The research also focuses on the important achievements of the market, research & development, and regional growth of the leading competitors operating in the market. The current trends of the global contraceptive drugs in conjunction with the geographical landscape of this vertical have also been included in this report.

The report offers intricate dynamics about different aspects of the global contraceptive drugs market, which aids companies operating in the market in making strategic development decisions. The study also elaborates on significant changes that are highly anticipated to configure growth of the global contraceptive drugs during the forecast period. It also includes a key indicator assessment that highlights growth prospects of this market and estimates statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).

Sample Link @ https://www.precedenceresearch.com/sample/1753

 Report Scope of the Contraceptive Drugs Market

Report CoverageDetails
Market Size by 2030USD 25.6 Billion
Growth Rate from 2022 to 2030

CAGR of 5.85%

Largest MarketNorth America 
Fastest Growing Market Asia-Pacific
Base Year2021
Forecast Period2022 to 2030
Segments CoveredProduct, Distribution Channel, Age Group, Geography

This study covers a detailed segmentation of the global contraceptive drugs market, along with key information and a competition outlook. The report mentions company profiles of players that are currently dominating the global contraceptive drugs market, wherein various developments, expansions, and winning strategies practiced and implemented by leading players have been presented in detail.

Key Players

  • Church & Dwight Co., Inc.
  • Reckitt Benckiser Group Plc
  • Veru, Inc.
  • Organon Group of Companies
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • The Cooper Companies, Inc.
  • Mayer Laboratories, Inc.
  • Agile Therapeutics
  • TherapeuticsmMD, Inc.
  • Bayer Ag
  • Afaxys, Inc.
  • Mithra Pharmaceuticals
  • Abbvie

Market Segmentation

 By Product

  • Oral
  • Pills
  • Intrauterine Devices (IUD)
    • Hormonal IUD
    • Nonhormonal IUD
  • Condoms
    • Male Condoms
    • Female Condoms
  • Vaginal Ring
  • Subdermal Implants
  • Injectable
  • Others

 By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Clinics
  • Online Channel
  • Public Channel & NGOs
  • Others

By Age Group

  • 15–24 years
  • 25–34 years
  • 35–44 years
  • Above 44 years

 By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Malaysia
    • Philippines
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC
    • North Africa
    • South Africa
    • Rest of the Middle East & Africa

Research Methodology

The research methodology adopted by analysts for compiling the global contraceptive drugs report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.

During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.

For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global contraceptive drugs market.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Contraceptive Drugs Market 

5.1. COVID-19 Landscape: Contraceptive Drugs Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Contraceptive Drugs Market, By Product

8.1. Contraceptive Drugs Market, by Product, 2022-2030

8.1.1 Oral

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Lead Acid

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Intrauterine Devices (IUD)

8.1.3.1. Market Revenue and Forecast (2017-2030)

8.1.4. Condoms

8.1.4.1. Market Revenue and Forecast (2017-2030)

8.1.5. Vaginal Ring

8.1.5.1. Market Revenue and Forecast (2017-2030)

8.1.6. Subdermal Implants

8.1.6.1. Market Revenue and Forecast (2017-2030)

8.1.7. Injectable

8.1.7.1. Market Revenue and Forecast (2017-2030)

8.1.8. Others

8.1.8.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Contraceptive Drugs Market, By Distribution Channel

9.1. Contraceptive Drugs Market, by Distribution Channel, 2022-2030

9.1.1. Hospital Pharmacy

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Retail Pharmacy

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. Clinics

9.1.3.1. Market Revenue and Forecast (2017-2030)

9.1.4. Online Channel

9.1.4.1. Market Revenue and Forecast (2017-2030)

9.1.5. Public Channel & NGOs

9.1.5.1. Market Revenue and Forecast (2017-2030)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Contraceptive Drugs Market, By Age Group 

10.1. Contraceptive Drugs Market, by Age Group, 2022-2030

10.1.1. 15–24 years

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. 25–34 years

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. 35–44 years

10.1.3.1. Market Revenue and Forecast (2017-2030)

10.1.4. Above 44 years

10.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Contraceptive Drugs Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Product (2017-2030)

11.1.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.1.3. Market Revenue and Forecast, by Age Group (2017-2030)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Product (2017-2030)

11.1.4.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.1.4.3. Market Revenue and Forecast, by Age Group (2017-2030)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Product (2017-2030)

11.1.5.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.1.5.3. Market Revenue and Forecast, by Age Group (2017-2030)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Product (2017-2030)

11.2.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.2.3. Market Revenue and Forecast, by Age Group (2017-2030)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Product (2017-2030)

11.2.4.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.2.4.3. Market Revenue and Forecast, by Age Group (2017-2030)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Product (2017-2030)

11.2.5.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.2.5.3. Market Revenue and Forecast, by Age Group (2017-2030)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Product (2017-2030)

11.2.6.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.2.6.3. Market Revenue and Forecast, by Age Group (2017-2030)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Product (2017-2030)

11.2.7.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.2.7.3. Market Revenue and Forecast, by Age Group (2017-2030)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Product (2017-2030)

11.3.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.3.3. Market Revenue and Forecast, by Age Group (2017-2030)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Product (2017-2030)

11.3.4.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.3.4.3. Market Revenue and Forecast, by Age Group (2017-2030)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Product (2017-2030)

11.3.5.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.3.5.3. Market Revenue and Forecast, by Age Group (2017-2030)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Product (2017-2030)

11.3.6.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.3.6.3. Market Revenue and Forecast, by Age Group (2017-2030)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Product (2017-2030)

11.3.7.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.3.7.3. Market Revenue and Forecast, by Age Group (2017-2030)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Product (2017-2030)

11.4.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.4.3. Market Revenue and Forecast, by Age Group (2017-2030)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Product (2017-2030)

11.4.4.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.4.4.3. Market Revenue and Forecast, by Age Group (2017-2030)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Product (2017-2030)

11.4.5.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.4.5.3. Market Revenue and Forecast, by Age Group (2017-2030)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Product (2017-2030)

11.4.6.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.4.6.3. Market Revenue and Forecast, by Age Group (2017-2030)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Product (2017-2030)

11.4.7.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.4.7.3. Market Revenue and Forecast, by Age Group (2017-2030)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Product (2017-2030)

11.5.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.5.3. Market Revenue and Forecast, by Age Group (2017-2030)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Product (2017-2030)

11.5.4.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.5.4.3. Market Revenue and Forecast, by Age Group (2017-2030)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Product (2017-2030)

11.5.5.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.5.5.3. Market Revenue and Forecast, by Age Group (2017-2030)

Chapter 12. Company Profiles

12.1. Church & Dwight Co., Inc.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Reckitt Benckiser Group Plc

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Veru, Inc.

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Organon Group of Companies

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Pfizer, Inc.

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Teva Pharmaceutical Industries Ltd.

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. The Cooper Companies, Inc.

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Mayer Laboratories, Inc.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Agile Therapeutics

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. TherapeuticsmMD, Inc.

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Contact Us:

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 774 402 6168

Email: sales@precedenceresearch.com

Website: https://www.precedenceresearch.com

 Blog: https://www.pharma-geek.com

 

Tags:

Post a Comment

0 Comments